169P Neoadjuvant pembrolizumab + chemotherapy followed by adjuvant pembrolizumab for treatment of high-risk, early-stage triple-negative breast cancer: A network meta-analysis

Abstract

Neoadjuvant pembrolizumab + chemotherapy (paclitaxel + carboplatin followed by anthracycline + cyclophosphamide) followed by adjuvant pembrolizumab received FDA approval for patients with high-risk, early-stage triple-negative breast cancer (eTNBC) based on improvements in pathological complete response (pCR) and event-free survival (EFS) compared to neoadjuvant chemotherapy in the phase III randomized controlled trial (RCT) KEYNOTE-522. Network meta-analysis (NMA) allows the efficacy of pembrolizumab + chemotherapy / pembrolizumab relative to other treatments to be estimated in the absence of head-to-head RCT evidence.